Cardiovascular Risk Factors and the Concentration of Asymmetric Dimethylarginine

Advances in Clinical and Experimental Medicine - Poland
doi 10.17219/acem/111808
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wroclaw Medical University

Related search

Asymmetric Dimethylarginine, the Promoter Factor of Cardiovascular Pathologies

Romanian Journal of Medical Practice
2019English

Decreased Levels of Homoarginine and Asymmetric Dimethylarginine in Children With Type 1 Diabetes: Associations With Cardiovascular Risk Factors but No Effect by Atorvastin

Journal of Pediatric Endocrinology and Metabolism
Child HealthEndocrinologyPerinatologyPediatricsMetabolismDiabetes
2015English

Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease: Insights From Prospective Clinical Trials

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2005English

Asymmetric Dimethylarginine and Asthma

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2014English

Association Between Body Mass Index, Asymmetric Dimethylarginine and Risk of Cardiovascular Events and Mortality in Norwegian Patients With Suspected Stable Angina Pectoris

PLoS ONE
Multidisciplinary
2016English

Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies

Atherosclerosis
Cardiovascular MedicineCardiology
2017English

Metabolism of Asymmetric Dimethylarginine and Its Clinical Significance

Turkish Journal of Biochemistry
BiochemistryClinical BiochemistryMolecular Biology
2012English

Asymmetric Dimethylarginine (ADMA) Accelerates Cell Senescence

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2005English

Homocysteine and Asymmetric Dimethylarginine (ADMA) in Neurological Diseases

JOURNAL OF ADVANCES IN CHEMISTRY
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy